Yuankai Shi, Qingyuan Zhang, Xiaonan Hong, Zhen Wang, Yuhuan Gao, Liqun Zou, Hong Cen, Lin Gui, Yufu Li, Jifeng Feng, Zhao Wang, Mingzhi Zhang, Chuan Jin, Weihua Zhang, Jianda Hu, Chengyun Zheng, Zhendong Zheng, Liling Zhang, Shaoshui Chen, Yunhong Huang, Yun Tang, Yajie Gao, Miaowang Hao, Xiaoling Li, Chunkang Chang, Haiyan Yang, Hui Wu, Lida Shen, Xiaoyan Ke, Liangming Zhang, Yaming Xi, Linhua Yang, Liangzhi Xie, Wenlin Gai, Yanan Ji
This study compared the efficacy, safety and immunogenicity of ripertamab (SCT400) and rituximab (Mabthera® ) combined with CHOP as the first-line treatment for Chinese patients with CD20-positive diffuse large B cell lymphoma (DLBCL). This is a randomized, patient-blind, multicenter, active-control, non-inferiority study with parallel design. Patients were randomly (2:1) to receive ripertamab combined with CHOP (S-CHOP) or rituximab (Mabthera® ) combined with CHOP (R-CHOP) for up to 6 cycles. The primary endpoint was the Independent Review Committee (IRC) assessed objective response rate (ORR) in full analysis set (FAS) and the per protocol set (PPS)...
December 2022: Hematological Oncology